Povofortay / Povorcitinib for Moderate-to-Severe Hidradenitis Suppurativa in Adults Refractory or Intolerant to Anti-TNF Therapy

As of October 2026, MARA’s assessment finds Povofortay / Povorcitinib’s reimbursement risk concentrated in comparator selection, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs patient population and subgroups: how closely the trial population matches the patients who would receive the drug in practice; payers often restrict funding to the groups where the evidence is strongest. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Immunology

This rating sits within MARA’s Immunology coverage, alongside 29 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The evidence includes two phase 3 trials showing statistically significant improvements in HiSCR50 versus placebo, with odds ratios of 1.6–1.9. However, there is no direct comparative data versus active therapies like adalimumab, secukinumab, or bimekizumab.

Does the economic case hold at the expected price? — Cost effectiveness

No economic model, ICER, or cost-utility analysis was identified for povorcitinib. Therefore, cost-effectiveness cannot be assessed.

Is there quality-of-life evidence payers weigh? — Quality of life

HRQoL instruments were used, and improvements were reported, but the data lacks complete numerical estimates and CIs for each PRO at each time point. No utility values were derived, limiting the assessment of HRQoL impact.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Short-term safety was broadly balanced with placebo, and long-term data showed common AEs like acne and infections. However, the data is insufficient for rare-event risk assessment.

Was the drug compared against what payers expect? — Comparator Selection

Placebo was used as a comparator, which is methodologically relevant for efficacy demonstration but weak for payer positioning in a post-anti-TNF indication. No active comparator data is available.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population included diverse demographics, but the small Japanese sample and minority anti-TNF-exposed fraction limit representativeness. Subgroup analysis data is incomplete and not peer-reviewed.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Povorcitinib is an oral tablet, which simplifies administration compared to injectable therapies. However, the exact training and monitoring requirements are not fully established.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use data specific to povorcitinib was presented, making it impossible to assess resource use and cost implications.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The trials were well-designed and replicated results across two phase 3 studies. However, the lack of an active comparator and reliance on sponsor-controlled data are limitations.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

While clinical robustness is supported by replicated trials, economic robustness is unevaluable due to the absence of economic data. Long-term effect size and safety remain uncertain.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.